Global pharmaceutical company Merck (NYSE: MRK) will be reporting results this Thursday before market open. Here’s what investors should know.

Merck beat analysts’ revenue expectations last quarter, reporting revenues of $16.4 billion, up 5% year on year. It was a slower quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates and full-year revenue guidance missing analysts’ expectations.

Is Merck a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Merck’s revenue to grow 1.9% year on year, a reversal from the 1.6% decrease it recorded in the same quarter last year.

Heading into earnings, analysts covering the company have mixed opinions about the business, with revenue estimates seeing both upward and downward revisions over the last 30 days. Merck rarely misses Wall Street’s revenue estimates.

With Merck being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for pharmaceuticals stocks. However, there has been positive investor sentiment in the segment, with share prices up 10.8% on average over the last month. Merck is down 6.7% during the same time .

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.